Background: The global burden of gastrointestinal cancers, including colorectal, stomach, and esophageal
cancers is rising steadily. Several therapeutic approaches have been considered for the treatment of GI
carcinomas. However, none showed to halt or cure the disease. There is a need to develop effective targeted molecular
therapies; mainly to overcome the adverse effects of currently used treatment regimens, as well as, to
benefit a large proportion of cancer patients who do not respond well to chemotherapeutics.
Methods: Epidermal growth factor receptor (EGFR) is one of the promising targets for cancer therapy. Through a
cascade of events, activation of EGFR plays an important role in the homeostasis and pathogenesis of various
disorders, including carcinomas of the gastrointestinal (GI) tract, ranging from oesophagitis to complex colon
Results: The GI carcinomas are associated with aberrant EGFR expression. In this review, emphasis was made on
various EFGR-associated signalling pathways, their mechanisms and role in the formation of gastrointestinal
Conclusion: The current EGFR-targeting therapeutics and an outline of various novel drug delivery systems that
could potentially be employed for targeting EGFR during cancer treatment were discussed. This would help
medical, pharmaceutical and other life science researchers in providing broad understanding of the work previously
conducted in this field.